STERIS plc (NYSE:STE) Shares Sold by Equitable Trust Co.

Equitable Trust Co. trimmed its position in STERIS plc (NYSE:STE) by 1.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,794 shares of the medical equipment provider’s stock after selling 178 shares during the period. Equitable Trust Co.’s holdings in STERIS were worth $3,103,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. West Coast Financial LLC lifted its position in shares of STERIS by 2.8% during the 3rd quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider’s stock valued at $398,000 after acquiring an additional 45 shares during the last quarter. Taylor Frigon Capital Management LLC lifted its position in shares of STERIS by 0.8% during the 2nd quarter. Taylor Frigon Capital Management LLC now owns 6,175 shares of the medical equipment provider’s stock valued at $1,356,000 after acquiring an additional 46 shares during the last quarter. J.Safra Asset Management Corp lifted its position in shares of STERIS by 77.9% during the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 53 shares during the last quarter. Mather Group LLC. lifted its holdings in shares of STERIS by 7.6% in the second quarter. Mather Group LLC. now owns 763 shares of the medical equipment provider’s stock valued at $172,000 after purchasing an additional 54 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of STERIS by 16.5% in the first quarter. EverSource Wealth Advisors LLC now owns 402 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 57 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Trading Up 1.7 %

Shares of NYSE:STE opened at $219.14 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.49 and a current ratio of 2.33. The stock’s 50-day moving average is $232.29 and its 200-day moving average is $227.64. STERIS plc has a 52-week low of $195.47 and a 52-week high of $248.24. The company has a market cap of $21.61 billion, a P/E ratio of 50.03 and a beta of 0.85.

STERIS (NYSE:STE) last released its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.03. The business had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.91%. The firm’s revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the company earned $2.03 earnings per share. Equities research analysts predict that STERIS plc will post 9.02 earnings per share for the current year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 1.04%. The ex-dividend date is Tuesday, November 19th. STERIS’s dividend payout ratio is 52.05%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on STE shares. StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. KeyCorp upped their price target on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 3rd. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Finally, Stephens reissued an “overweight” rating and set a $260.00 target price on shares of STERIS in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $253.00.

Insider Transactions at STERIS

In other news, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.14% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.